Free Trial

Evolus Q1 2024 Earnings Report

Evolus logo
$10.89 +0.02 (+0.18%)
(As of 05:51 PM ET)

Evolus EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.15
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Evolus Revenue Results

Actual Revenue
$59.33 million
Expected Revenue
$58.78 million
Beat/Miss
Beat by +$550.00 thousand
YoY Revenue Growth
N/A

Evolus Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry. 

Evolus Earnings Headlines

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
See More Evolus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evolus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evolus and other key companies, straight to your email.

About Evolus

Evolus (NASDAQ:EOLS), a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

View Evolus Profile

More Earnings Resources from MarketBeat

Upcoming Earnings